Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    21334595 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)
Condition: Type 2 Idiopathic Macular Telangiectasia
Intervention: Drug: Intravitreal injection ranibizumab

Study has passed its completion date and status has not been verified in more than two years.